Table 3. Lifetable Estimates for Incident Liver Cancer and Mortality by Sex and HFE Genotypes .
| Outcome | No variants | C282Y homozygotes | Difference, % | ||||
|---|---|---|---|---|---|---|---|
| Cases | Survival function | Incident diagnosis (95% CI), %a | Cases | Survival function | Incident diagnosis (95% CI), %a | ||
| Liver cancerb | |||||||
| Male age group, y | |||||||
| 40-45 | 0 | 1.0000 | 0 | 1 | |||
| 46-50 | 1 | 0.9999 | 0.0 (0.0-0.1) | 0 | 1 | ||
| 51-55 | 3 | 0.9996 | 0.0 (0.0-0.1) | 1 | 0.9909 | 0.9 (0.1-6.3) | 0.9 |
| 56-60 | 8 | 0.9990 | 0.1 (0.1-0.2) | 0 | 0.9909 | 0.9 (0.1-6.3) | 0.8 |
| 61-65 | 11 | 0.9983 | 0.2 (0.1-0.3) | 2 | 0.9799 | 2.0 (0.6-6.3) | 1.8 |
| 66-70 | 25 | 0.9969 | 0.3 (0.2-0.4) | 4 | 0.9617 | 3.8 (1.8-8.1) | 3.5 |
| 71-75 | 21 | 0.9944 | 0.6 (0.4-0.7) | 4 | 0.9279 | 7.2 (3.9-13.1) | 6.6 |
| Female age group, y | |||||||
| 40-45 | 0 | 1.0000 | 0 | 1 | |||
| 46-50 | 3 | 0.9997 | 0.0 (0.0-0.1) | 0 | 1 | ||
| 51-55 | 1 | 0.9997 | 0.0 (0.0-0.1) | 0 | 1 | ||
| 56-60 | 2 | 0.9995 | 0.0 (0.0-0.1) | 0 | 1 | ||
| 61-65 | 16 | 0.9988 | 0.1 (0.1-0.2) | 0 | 1 | ||
| 66-70 | 19 | 0.9979 | 0.2 (0.2-0.3) | 1 | 0.9962 | 0.4 (0.0-2.7) | 0.2 |
| 71-75 | 17 | 0.9964 | 0.4 (0.3-0.5) | 0 | 0.9962 | 0.4 (0.0-2.7) | 0.0 |
| Mortalityc | |||||||
| Male age group, y | |||||||
| 40-45 | 18 | 0.997 | 0 | 1.000 | |||
| 46-50 | 131 | 0.990 | 1.0 (0.8-1.3) | 3 | 0.985 | 1.5 (0.5-4.6) | 0.5 |
| 51-55 | 286 | 0.980 | 2.0 (1.8-2.3) | 3 | 0.975 | 2.5 (1.1-5.6) | 0.5 |
| 56-60 | 504 | 0.965 | 3.5 (3.2-3.9) | 4 | 0.963 | 3.7 (2.0-6.9) | 0.2 |
| 61-65 | 980 | 0.943 | 5.7 (5.4-6.1) | 17 | 0.927 | 7.3 (5.0-10.7) | 1.6 |
| 66-70 | 1814 | 0.909 | 9.1 (8.8-9.5) | 27 | 0.880 | 12.0 (9.2-15.6) | 2.9 |
| 71-75 | 2086 | 0.849 | 15.1 (14.7-15.5) | 27 | 0.805 | 19.5 (15.8-24.0) | 4.4 |
| Female age group, y | |||||||
| 40-45 | 22 | 0.997 | 0.3 (0.2-0.5) | 0 | 1.000 | ||
| 46-50 | 90 | 0.993 | 0.7 (0.5-0.9) | 2 | 0.993 | 0.7 (0.2-2.8) | 0.0 |
| 51-55 | 240 | 0.986 | 1.4 (1.2-1.6) | 2 | 0.988 | 1.2 (0.5-3.3) | −0.1 |
| 56-60 | 380 | 0.977 | 2.3 (2.1-2.5) | 7 | 0.973 | 2.7 (1.5-4.9) | 0.4 |
| 61-65 | 711 | 0.964 | 3.6 (3.4-3.8) | 8 | 0.959 | 4.1 (2.6-6.5) | 0.6 |
| 66-70 | 1176 | 0.945 | 5.5 (5.3-5.8) | 15 | 0.936 | 6.4 (4.5-8.9) | 0.8 |
| 71-75 | 1271 | 0.910 | 9.0 (8.7-9.3) | 24 | 0.883 | 11.7 (9.1-15.0) | 2.7 |
a
Lifetable projections based on observed 5-year age group–specific incidence rates from ages 40 and 75 years (eg, in male p.C282Y homozygotes, 7.2% were projected to develop liver cancer by age 75 years compared with 0.6% of men without HFE variants; difference, 6.6%).
b
Liver cancer estimates are based on the subset of participants with primary care data (n = 209 811). Individuals with prevalent diagnosis at baseline were excluded.
c
All-cause mortality estimates based on total cohort (n = 451 186).